UNICREDIT BANK/CALL/BIOGEN IDEC/320/0.1/15.01.25 | Market Closed - BOERSE MUENCHEN 03:41:55 2024-05-17 pm EDT | ||
| 0.56 EUR | +16.67% |
|
| Current month | +80.65% | ||
| 1 month | +211.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.56 | +16.67% |
| 24-05-16 | 0.48 | -17.24% |
| 24-05-15 | 0.58 | +34.88% |
| 24-05-14 | 0.43 | +4.88% |
| 24-05-13 | 0.41 | +5.13% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD31TJ |
| ISIN | DE000HD31TJ0 |
| Date issued | 2024-02-26 |
| Strike | 320 $ |
| Maturity | 2025-01-15 (243 Days) |
| Parity | 10 : 1 |
| Emission price | 0.59 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.72 € |
|---|---|
| Lowest since issue | 0.009 € |
| Spread | 0.02 € |
| Spread % | 3.39% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
285.9
USD
Spread / Average Target
+24.01%
- Stock Market
- Warrants
- Warrant
